Reports Q4 revenue $31.3M, consensus $37.45M. Cash, cash equivalents and marketable securities were $565.2M as of December 31, 2022, compared to $849.3M as of December 31, 2021. "REGENXBIO enters the year with a strong pipeline of AAV Therapeutics. One year ago, we introduced our ‘5x’25’ strategy and I remain confident that we will achieve this goal," said Kenneth T. Mills, President and CEO "Our lead candidate, RGX-314, is being developed in partnership with AbbVie for the treatment of wet AMD and diabetic retinopathy, which present opportunities to make an impact in eye care for millions of patients. In 2022, we made meaningful progress with our RGX-314 trial enrollment objectives and geographic expansion planning. We also established in-house manufacturing to meet global clinical and commercial regulatory standards. We remain committed to developing treatments for rare diseases and made significant advancements with our pipeline of treatments for diseases such as Batten, Duchenne, Hurler and Hunter Syndrome, the latter of which we expect will support a second BLA filing using the accelerated approval pathway. Our history, science, resources, people and values combine to make us an industry leader in gene therapy and in the development of potentially ground-breaking therapies. We look forward to providing additional updates about our progress in 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGNX:
- REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights
- Regenxbio announces ‘positive’ interim data from Phase I/II trial of RGX-111
- Regenxbio announces additional ‘positive’ interim data from CAMPSIITE trial
- Pathway Development Consortium announces publication on DMD
- Regenxbio announces Phase 1/2 trial of RGX-202 in Duchenne